Bio-Techne (TECH) stock saw a quick boost as investors responded to reports that the Trump administration is considering a two-year extension of Affordable Care Act subsidies. This development is ...
ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an ...
Nov 5 (Reuters) - Biotech firm Bio-Techne (TECH.O), opens new tab on Wednesday missed Wall Street estimates for first-quarter revenue, hurt by subdued demand for its products, sending its shares down ...
MINNEAPOLIS (AP) — MINNEAPOLIS (AP) — Techne Corp. (TECH) on Wednesday reported fiscal first-quarter earnings of $38.2 million. On a per-share basis, the Minneapolis-based company said it had profit ...
Life sciences company Bio-Techne (NASDAQ:TECH) missed Wall Street’s revenue expectations in Q3 CY2025, with sales falling 1% year on year to $286.6 million. Its non-GAAP profit of $0.42 per share was ...
Saguaro Biosciences, a pioneer in non-toxic live cell reagents for enhanced drug insights, announces a new distribution agreement with Bio-Techne Corporation (NASDAQ:TECH), a global provider of life ...
Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit Establishes a framework to define and propose ...
RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...
Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation, a global ...
Bio-Techne Corporation is a market leader in life science reagents, well-positioned for long-term growth in cell and gene therapeutics and organoid solutions. Despite strong fundamentals and recurring ...
Shares of Bio-Techne Corp. TECH slipped 4.13% to $49.50 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.84% to 5,982.72 and ...
The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback